期刊
RHEUMATOLOGY
卷 58, 期 -, 页码 4-16出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/key432
关键词
cytokines; signal transduction; Janus kinases; kinase inhibitors; autoimmunity; inflammation
类别
资金
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Intramural Research Program
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001251] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041106, ZICAR041181, ZIAAR041159] Funding Source: NIH RePORTER
Cytokines are critical mediators of diverse immune and inflammatory diseases. Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance. We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents. Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases. We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据